<DOC>
	<DOCNO>NCT00141479</DOCNO>
	<brief_summary>The purpose study investigate safe treatment interruption interval ( ) re-initiation bifeprunox therapeutic dose . The study duration approximately 7 10 week .</brief_summary>
	<brief_title>To Evaluate Impact Treatment Interruption Re-initiation Bifeprunox</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Diagnosis Schizophrenia Schizoaffective disorder 1855 year Subjects acutely psychotic Subjects current Axis I primary psychiatric diagnosis schizophrenia Subjects significant risk suicide Subjects seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Treatment interruption reinitiation</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective disorder</keyword>
</DOC>